Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,045 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC. Loriot MA, et al. Among authors: thomas f. Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Bull Cancer. 2018. PMID: 29486921 Free article. Review. French.
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F. Le Louedec F, et al. Among authors: thomas f. Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13. Br J Clin Pharmacol. 2019. PMID: 30811063 Free PMC article. Clinical Trial.
Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines.
Maillard M, Eche-Gass A, Ung M, Brice A, Marsili S, Montastruc M, Puisset F, Thomas F. Maillard M, et al. Among authors: thomas f. Cancer Chemother Pharmacol. 2021 Apr;87(4):579-583. doi: 10.1007/s00280-021-04233-1. Epub 2021 Feb 15. Cancer Chemother Pharmacol. 2021. PMID: 33587160
Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation.
Thomas F, Maillard M, Launay M, Tron C, Etienne-Grimaldi MC, Gautier-Veyret E, Haufroid V, Pallet N, Royer B, Narjoz C, Schmitt A; Groupe de Pharmacologie Clinique Oncologique (GPCO-UNICANCER). Thomas F, et al. Ann Oncol. 2021 Jun;32(6):810-811. doi: 10.1016/j.annonc.2021.02.020. Epub 2021 Mar 1. Ann Oncol. 2021. PMID: 33662499 Free article. No abstract available.
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Maillard M, Launay M, Royer B, Guitton J, Gautier-Veyret E, Broutin S, Tron C, Le Louedec F, Ciccolini J, Richard D, Alarcan H, Haufroid V, Tafzi N, Schmitt A, Etienne-Grimaldi MC, Narjoz C, Thomas F; Groupe de Pharmacologie Clinique Oncologique (GPCO). Maillard M, et al. Among authors: thomas f. Br J Clin Pharmacol. 2023 Feb;89(2):762-772. doi: 10.1111/bcp.15536. Epub 2022 Oct 3. Br J Clin Pharmacol. 2023. PMID: 36104927 Free PMC article.
Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.
Loison G, Bouges Le Royer H, Marsili S, Brice A, Vintejoux J, Yakoubi M, Sirgue H, Chatelut E, Etienne-Grimaldi MC, Thomas F; on behalf of the GPCO-UNICANCER group. Loison G, et al. Among authors: thomas f. Clin Chem Lab Med. 2024 Jan 11;62(6):e129-e131. doi: 10.1515/cclm-2023-1096. Print 2024 May 27. Clin Chem Lab Med. 2024. PMID: 38198224 Free article. No abstract available.
2,045 results